The corporate history of Genentech in the United States

Genome Engineering Technologies, Inc., Inc., is a venture capitalist named Gene EngineersFounded in 1976 by Swanson and biochemist Dr. Herbert Boyer, the biotechnology company is considered the founding father of the biotechnology industry. The founder, Dr. Boyer, is a pioneer in DNA recombinant technology.

In 1973, Boyer and colleague Stanley Cohen used restriction enzymes to cut out the desired piece of lead from a DNA molecule and attach it to a plasmid. In 1977, the company manufactured the hormone somatostatin; In 1978, the company synthesized human insulin. In March 2008, Genentech had more than 11,000 employees and was CEO Arthur D

levinson。On March 26, 2009, the Swiss pharmaceutical group Roche acquired the company in full for approximately $46.8 billion.

In 1995, researchers at IDEC Pharmaceuticals in San Diego developed a new drug called Rituxan, the first monoclonal antibody drug to successfully target cancer cell proteins. Rituxan is a monoclonal antibody that picks out cancer cells and gives them to the immune system to destroy. Rituxan ran into difficulties due to funding bottlenecks, and Genentech decided to invest $57 million to help IDEC continue research and development, on the condition that it acquire a 65% stake in Rituxan.

With funding from Genentech, Rituxan has received satisfactory results in clinical trials in patients with early-stage lymphoma and was approved by the FDA in 1997 for the treatment of early-stage lymphoma**. Now, Rituxan is the best-selling drug in the United States, and it acts specifically on a special type of white blood cell that causes non-Hodjekin lymphoma. In addition, Rituxan is less toxic.

In 2003, Rituxan's sales reached 100 million US dollars. Genentech and Biogen (at this time IDEC has been merged into Biogen) share the U.S. market for Rituxan, while Roche shares the market with Zenyaku Kogyo in Japan and has exclusive rights to operate Rituxan in the rest of the world. Since its inception, more than 300,000 patients worldwide have received Rituxan**.

Genentech was ranked No. 1 in Fortune Magazine's 2006 "Top 100 Employee Friendly Rankings." Although Genentech has been on the list for thirteen consecutive years, this is the first time the company has made the No. 1 list. In 2007, Genentech fell to second place after Google.

In 2008, it ranked fifth, in 2009 it ranked seventh, in 2010 it ranked 19th, and in 2011 it ranked 35th. The ranking is composed of a questionnaire survey of anonymous employees and a comparison of company rules and culture.

Genentech was ranked No. 1 in the "Top 100 Working Mother-Friendly List" this year.

Genentech was a member of Business Ethics magazine's 2006 Top 100 Corporate Citizens.

Genentech was named a Best Employer by Science magazine on October 7, 2010, and the company has been featured in the magazine for nine years.

In March 2008, Genentech was selected as the most admired pharmaceutical company by Fortune Star for the second year in a row.

In July 2010, Genentech was selected as one of the "Top 100 Friendly Companies in IT" by Computerworld magazine.

In December 2008, Genentech CEO Arthur DLevinson) was named the "best" CEO of 2008 with 93% support.

Genentech appeared in the 2011 documentary.